Tafenoquine
Edina Avdic, Pharm.D.
Pediatric Dosing Author: Bethany Sharpless Chalk, Pharm.D., BCPPS
Tafenoquine is a topic covered in the
Johns Hopkins ABX Guide.
To view the entire topic, please log in or purchase a subscription.
Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:

-- The first section of this topic is shown below --
INDICATIONS
- Two different brand names were FDA approved in 2018
- Krintafel™- radical cure (prevention of relapse) of Plasmodium vivax malaria in patients ≥16 years old who are receiving appropriate antimalarial therapy for acute P. vivax infection.
- Please note that tafenoquine is NOT indicated for the treatment of acute P. vivax malaria.
- Arakoda™-prophylaxis of malaria in patients ≥18 years of age
-- To view the remaining sections of this topic, please log in or purchase a subscription --
INDICATIONS
- Two different brand names were FDA approved in 2018
- Krintafel™- radical cure (prevention of relapse) of Plasmodium vivax malaria in patients ≥16 years old who are receiving appropriate antimalarial therapy for acute P. vivax infection.
- Please note that tafenoquine is NOT indicated for the treatment of acute P. vivax malaria.
- Arakoda™-prophylaxis of malaria in patients ≥18 years of age
There's more to see -- the rest of this topic is available only to subscribers.
© 2000–2022 Unbound Medicine, Inc. All rights reserved